| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers W > Headlines for Wyeth > News item |
Wyeth announces Scottish collaboration, invests $86 million in biomarker research
By Elaine Rigoli
Tampa, Fla., April 3 - Wyeth Pharmaceuticals and the Health Ministry of Scotland announced the creation of the Translational Medicine Research Collaboration, which will be comprised of the four major medical universities in Scotland (Aberdeen, Dundee, Edinburgh and Glasgow), as well as Wyeth, Scottish Enterprise and the National Health Service.
Wyeth is investing almost $86 million toward this initiative, according to a news release.
Translational medicine is a new field that integrates the study of the elements of disease with the development of novel therapies and diagnostics.
A goal of these studies is the identification of "biomarkers" or specific signals within patient populations that can be used to select the best therapy for an individual patient.
An important outcome of the combined research is speedier, more efficient and more effective clinical testing of new therapies where a candidate drug is studied in smaller patient groups, officials said.
The research model will be based on a central core laboratory working with "Centers of Excellence" at each of the universities, the release said.
The laboratory will be based at the University of Dundee. The laboratory will interact with the "Centers of Excellence" at each of the universities' medical schools where specialized clinical research programs will be implemented, the release said.
Madison, N.J.-based Wyeth develops products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.